ClinicalTrials.gg

Program

Benzydamine

Also written as “benzydamine HCl”, “Benzydamine Hydrochloride 0.15% w/v oromucosal solution” and “Benzydamine Hydrochloride 0.15% Oral Rinse”.

Its studies are mostly in Stomatitis · Head and Neck Neoplasms, led by 3 companies.

Furthest: phase 4, since Jun 23, 20214 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Angelini Pharma20 open or runningphase 4since Jun 23, 2021Jun 23, 2021none ahead
E2Bio Life Sciences11 open or runningphase 2since Apr 11, 2022Apr 11, 2022none ahead
Johnson & Johnson10 open or runningphase 3since Jan 9, 2003Jan 9, 2003none ahead

Also a collaborator on its studies: cross-research-s-a, ppd-development-lp and angelini.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2003First study: phase 3 study in StomatitisNew to Johnson & JohnsonJohnson & Johnson · NCT00051441 · 605 enrolled
  2. Jun 23, 2021Angelini Pharma's first study: phase 4 study in Head and Neck NeoplasmsNew to Angelini PharmaAngelini Pharma · NCT05055726 · 100 enrolled · Hungary, Poland
  3. Apr 11, 2022E2Bio Life Sciences's first study: phase 2 study in StomatitisNew to E2Bio Life SciencesE2Bio Life Sciences · NCT05338398 · 100 planned · Armenia
  4. Sep 9, 2025Phase 1 study in Healthy VolunteersAngelini Pharma · NCT07199543 · 120 enrolled · Switzerland

TargetBeta

PTGS1 →PTGS2 →read by rule
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07199543Healthy Volunteers · Switzerland1CompletedAngelini PharmaJul 20, 2025120
NCT05338398Stomatitis · Armenia2By invitationE2Bio Life SciencesOct 30, 2023100
NCT05055726Head and Neck Neoplasms · Hungary, Poland4CompletedAngelini PharmaSep 5, 2022100
NCT00051441Stomatitis3CompletedJohnson & Johnson605

How it is read

Names in the registry

  • “benzydamine HCl”, 1 entry
  • “Benzydamine”, 1 entry
  • “Benzydamine Hydrochloride 0.15% w/v oromucosal solution”, 1 entry
  • “Benzydamine Hydrochloride 0.15% Oral Rinse”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.